Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03611101 · ClinicalTrials.gov registry record
Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials
A clinical trial, sponsored by Meridian Bioscience.
- Completed
- Registry status
- 124
- Enrollment target
NCT03611101 is a clinical trial that has completed, run by Meridian Bioscience. The registered enrollment target is 124 participants.
The verdict
NCT03611101 has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- 124 participants
- Enrollment target
Study Summary
This is a companion study assessing the ¹³C-Methacetin Breath Test (MBT) in subjects participating in the Bristol Myers-Squibb (BMS) NCT03486899 and NCT03486912 referenced studies using study drug BMS-986036.
Interventions
- DRUG BMS-986036
- COMBINATION_PRODUCT ¹³C-Methacetin Breath Test
- DEVICE BreathID MCS device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2018-05-04 |
| Est. Completion | 2021-11-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03611101
The ClinicalTrials.gov registry entry for NCT03611101 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meridian Bioscience, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BMS-986036 is the first listed.
NCT03611101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03611101 about?
NCT03611101 is a clinical study titled "Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials". This is a companion study assessing the ¹³C-Methacetin Breath Test (MBT) in subjects participating in the Bristol Myers-Squibb (BMS) NCT03486899 and NCT03486912 referenced studies using study drug BMS-986036.
What is the current status of trial NCT03611101?
This trial is currently completed. The enrollment target is 124 participants. The study started on 2018-05-04. Estimated completion is 2021-11-10.
What interventions are being tested in trial NCT03611101?
The interventions under investigation include: BMS-986036 (DRUG), ¹³C-Methacetin Breath Test (COMBINATION_PRODUCT), BreathID MCS device (DEVICE).
Who is sponsoring clinical trial NCT03611101?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.